Newron bags €40m EIB loan
The EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2180 entries already.
Entries by Thomas Gabrielczyk
TES Pharma presents new treatment approach towards AKI and NALFD
TES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
Asthma needs to be targeted more specifically
Up to now, researchers believed that lung remodeling follows an autoimmune inflammation triggered by components of the extracellular matrix. In August, British scientists provided a more accurate view of the processes in the lung tissue, opening up a way to optimise failed mid-stage clinical candidates.
MEPs vote for ban of single-use plastics
The European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.
AstraZeneca and Innate Pharma in US$5bn oncology deal
AstraZeneca plc has extended its immunoncology pipeline by an extension of its partnership with French Innate Pharma SA.
Takeda strikes US$640m deal with Enterome
French Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
EMA recommends four biologicals for market
The European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Companies at EFIB set to drive the bioeconomy
Industrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.
Innovative delivery: dual-chamber systems
As the global demand for injectables grows, so does the demand for innovative delivery systems. For lyophilised forms, dual-chamber systems offer advantages. They have been on the market since the mid-1980s, mainly for emergency or chronic medication. The systems have been developed for the convenience of the patients/caregivers, but they also offer benefits for the pharma/biotech companies in regards to low residual volume and increased API yield.
Pioneers in the synbio revolution
Is synthetic biology on the cusp of unlocking the next industrial revolution? A major roadblock is the ability to synthesise DNA for R&D in ways that are both cheap and efficient. Established players in the field believe the answer lies in miniaturising standard chemical processes and running them in parallel systems. But the new kids on the block are betting on a completely new process that involves enzymes.